NCT06687421Recruiting
Implementation of Precision Medicine in High-risk Prostate Cancer
Swedish Prostate Cancer Initiative for Novel Treatment Regimens - Real, Implementation of Precision Medicine in High-risk Prostate Cancer
Source: ClinicalTrials.gov · Last updated 3 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This project's objective is to initiate a prospective non-interventional clinical study to perform full molecular characterization and subtyping of the primary tumor prostate cancer patients. It will identify, compare, and select biomarkers for treatment response in high-risk/metastatic prostate cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5500 (estimated)
- First submitted
- 16 Oct 2024
- Start date
- 10 Jun 2024
- Primary completion date
- Dec 2054
- Lead sponsor
- Andreas Josefsson
- Diseases
- Prostate cancer
- NCT number
- NCT06687421
What you commit to
- Study type: Observational
- Planned participants: 5500
- From 10 Jun 2024 to the primary completion date, Dec 2054
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Difficulties understanding information about the study due to linguistic, cognitive or other reason
Who the study is looking for
- Men investigated for suspected prostate cancer
- Signed consent form
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Urology, Umeå University Hospital, Region Västerbotten Coordinator of this site? Confirm its status | Umeå | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.